⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 6, 2025Open Access

Table 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors

Christopher H. Lieu Heinz‐Josef Lenz Al B. Benson Xue Meng Uk-Il Kim Song Hyun Kim Kyungjin Kim Moo Je Sung

View Full Paper

Ask AI

Bookmark

Share

Key Points

Adverse events related to basroparib were summarized, indicating outcomes of treatment.
Patients with advanced-stage solid tumors showed varying responses during dose-escalation.
The phase I study evaluated the safety and tolerability of basroparib.
Considering the advanced-stage tumors, findings support ongoing research into tankyrase inhibitors.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Phase I study examines dose-escalation and adverse events in patients with solid tumors, suggesting safety trends.

Abstract

Summary of AEs related to basroparib.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lieu et al. (2025) studied this question.

synapsesocial.com/papers/68e5c1ba6950a706b22b5383 https://doi.org/10.1158/2767-9764.30284995

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025 · 1 citations
2Table 4 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
3Figure 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
4Figure 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
5Data from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025

A First-In-Human Dose-Escalation Phase 1 Study of Basroparib (STP1002), a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
TABLE 2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors2024
TABLE 2 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors2024